Therapies for vitiligo

Drug Therapy in Dermatology

Volumn , Issue , 2016, Pages 339-356

  Grimes, Pearl E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33644838818     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14006-21     Document Type: Chapter

References (69)

1. Grimes PE. Diseases of hypopigmentation. In: Sams WM, Lynch PJ, eds. Principles and Practice of Dermatology. 2nd ed. New York: Churchill-Livingstone, 1996, pp. 873-885.
2. Boissy R, LePoole C. Vitiligo. Sem Cut Med Surg 16:3-14, 1997.
3. Kovacs SO. Vitiligo. J Am Acad Dermatol 38:647-666, 1998.
4. Schwartz RA, Janniger CK. Vitiligo. Cutis 60:239-244, 1997.
5. Grimes PE, Sevall JS, Wojdani A. Cytomegalovirus DNA identified in skin biopsy specimens of patients with vitiligo. J Am Acad Dermatol 35:21-26, 1996.
6. Grimes PE. Vitiligo: an overview of therapeutic approaches. Dermatol Clin 11:325-337, 1993.
7. Grimes PE. Psoralen photochemotherapy for vitiligo. Clin Dermatol 15:921-926, 1997.
8. Nordlund JJ, Halder RM, Grimes PE. Management of vitiligo. Dermatol Clin 11:27-33, 1993.
9. Nordlund JJ, Grimes PE, Halder RM. Guidelines for treatment of vitiligo. J Am Acad Dermatol 15:921-926, 1997.
10. Kumari F. Vitiligo treated with topical clobetasol proponate. Arch Dermatol 120:631-635, 1984.
11. Geraldez CB, Gutierrez G. A clinical trial of clobetasol propionate in Filipino vitiligo patients. Clin Therapeutics 9:474-482, 1987.
12. Farah FS, Kurban AK, Chaglassian HT. The treatment of vitiligo with psoralens and triamcinolone by mouth. Br J Dermatol 79:89-91, 1967.
13. El Mofty AM. Vitiligo and Psoralens. New York: Pergamon Press, 1968.
14. El Mofty AM. A preliminary clinical report on the treatment of leucoderma with Ammi majus linn. J Egypt Med Assoc 31:631-660, 1948.
15. Fitzpatrick TB. The psoralen story: photochemotherapy and photoprotection. Proceedings of the International Congress: Psoralens in 1988. 1989: pp. 5-10.
16. Parrish JA, Fitzpatrick TB, Shea G, et al. Photochemotherapy of vitiligo: use of orally administered psoralens and a high-intensity long-wave ultraviolet light system. Arch Dermatol 112:1531-1534, 1976.
17. Honig B, Morison WL. Photochemotherapy beyond psoriasis. J Am Acad Dermatol 31:775-790, 1994.
18. Ortonne JP, MacDonald DM, Micoud A, et al. PUVA-induced repigmentation of vitiligo: a histochemical (split DOPA) and ultrastructural study. Br J Dermatol 101:1-7, 1979.
19. Cui J, Shen L, Wang G. Role of the hair follicles in repigmentation of vitiligo. J Invest Dermatol 97:410-416, 1991.
20. Kao CH, Hsen SY. Comparison of the effect of 8-methoxypsoralen (8-MOP) plus UVA (PUVA) on human melanocytes in vitiligo vulgaris and in vitro. J Invest Dermatol 98:734-740, 1992.
21. Morelli JG, Yohn JJ, Zekman T, et al. Melanocyte movement in vitro: role of matrix proteins and integrin receptors. J Invest Dermatol 101:605-608, 1993.
22. Abdel-Naser MB, Hann SK, Bystryn JC. Oral psoralen with UVA-A therapy releases circulating growth factor (A) that stimulates oil proliferation. Arch Dermatol 133:1530-1533, 1997.
23. Morison WL. In vivo effects of psoralens plus longwave ultraviolet radiation on immunity. J Natl Cancer Inst 66:243-246, 1984.
24. Morison WT, Parrish JA, McAuliffe DJ, et al. Sensitivity of mononuclear cells to PUVA: effect on subsequent stimulation with mitogens and on exclusion of trypan blue dye. Clin Exp Dermatol 6:273-278, 1981.
25. McNeely W, Goa KL. 5-Methoxypsoralen: a review of its effects in psoriasis and vitiligo. Drugs 56:667-690, 1998.
26. Hann SK, Cho MY, Im S, et al. Treatment of vitiligo with oral 5-methyoxypsoralen. J Dermatol 18:324-329, 1991.
27. Stern RS, Lange R. Nonmelanoma skin cancer occuring in patients treated with PUVA 5 to 10 years after first treatment. J Invest Dermatol 91:120-124, 1998.
28. Stern RS, Thibodeau LA, Kleinerman RA, et al. Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. N Engl J Med 300:809-813, 1997.
29. Halder R, Battle EF, Smith EM. Cutaneous malignancies in patients treated with psoralen photochemotherapy (PUVA) for vitiligo. Arch Dermatol 131:734-735, 1995.
30. Lowe NJ, Ukingarten D, Bourget T, May LS. PUVA therapy for psoriasis: comparison of oral and bathwater delivery of 8-methoxypsoralen. J Am Acad Dermatol 14:754-760, 1986.
31. Mai DW, Ossohuntro C, Dijksta J WE, Bailin P. Childhood vitiligo successfully treated with bath PUVA. Ped Dermatol 15:53-55, 1998.
32. Cormane RH, Siddiqui AH, Nangerman IM. Photochemotherapy of vitiligo with oral phenylalanine. J Invest Dermatol 80:367-370, 1983.
33. Antiniou C, Schulpis H, Michas T, et al. Vitiligo therapy with oral and topical phenylalanine and UVA exposure. Int J Dermatol 28:545-547, 1989.
34. Siddiqui AH, Stolk LML, Bhaggol R, et al. L-phenylalanine and UVA irradiation in the treatment of vitiligo. J Dermatol 188:215-218, 1994.
35. Koster W, Wisekmann A. Photherapie mit UV-B bei vitiligo. Z Hautkr 65:1022-1029, 1990.
36. Westerhof W, Nievweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs. topical psoralen plus UV-A. Arch Dermatol 133:1525-1528, 1997.
37. Abdel-Fattah A, Aboul-Enein MN, Wassel G, et al. An approach to the treatment of vitiligo by khellin. Dermatologica 165:136-140, 1982.
38. Ortel B, Tanew A, Honigsman H. Treatment of vitiligo with khellin and ultraviolet light. J Am Acad Dermatol 18:693-701, 1988.
39. Dushet P, Schwartz T, Pusch M, et al. Marked increase of liver transaminases after khellin and UVA therapy. J Am Acad Dermatol 21:592-593, 1989.
40. Orrecchia G, Perfetti L. Photochemotherapy with topical khellin and sunlight. J Dermatol 184:120-123, 1992.
41. Miyares-Cao C. Melagenina: a Cuban product. A new and effective drug for the treatment of vitiligo. Series of National Reports. Republic of Cuba, Havana, 1986.
42. Mandel AS, Haberman HP. Non-PUVA nonsurgical therapies for vitiligo. Clin Dermatol 15:907-919, 1997.
43. Suite M, Quamina DB. Treatment of vitiligo with topical melagenina-a human placental extract. J Am Acad Dermatol 24:1018-1019, 1991.
44. Schallreuter KU, Wood JM, Lemke KR, et al. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure:a case study on 33 patients. Dermatology 190:223-229, 1995.
45. Montes LF, Diaz ML, Lajous J, Garcia NJ. Folic acid and vitamin B12 in vitiligo:a nutritional approach. Cutis 50:39-42, 1992.
46. Juhlin I, Olsson MJ. Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. ACTA Derm Venereol 77:460-462, 1997.
47. Grimes PE, Wojdani A, Loeb LJ, et al. The effects of isoprinosine treatment on repigmentation and immunologic aberrations in vitiligo. J Invest Dermatol 98(abstr):534, 1992.
48. Pasricha JS, Khera V. Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading disease. Int J Dermatol 33:584-587, 1994.
49. Nihel Y, Nishibu A, Kaneko F. Suplatast fosilate (IPD), a new immunoregulator, is effective in vitiligo treatment. J Dermatol 25:250-255, 1998.
50. Gokdale BB. Cyclophosphamide and vitiligo. Int J Dermatol 18:92, 1979.
51. VanScott EJ, Yu RJ. Melanogenesis from topical mechlorethamine and analogues in skin of hairless mice and in vitiligo. J Invest Dermatol 65:476-478, 1975.
52. Parsud D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatol 197:167-170, 1998.
53. Muto M, Furumoto H, Ohmura A, et al. Successful treatment of vitiligo with a sex steroid-thyroid hormone mixture. J Dermatol 22:770-772, 1995.
54. Oliver EA, Schwartz L, Warren LH. Occupational leukoderma. Arch Dermatol Syphylol 42:993-1014, 1940.
55. Mosher DB, Parrish JA, Fitzpatrick TB, et al. Monobenzylether of hydroquinone:a retrospective study of 18 severely affected patients. Br J Dermatol 97:669-679, 1977.
56. Nordlund JJ, Fazet B, Kirkwood J, Lerner AB. Dermatitis produced by applications of monobenzone in patientswith active vitiligo. Arch Dermatol 121:1141-1144, 1985.
57. Falabella R. Epidermal grafting: an original technique and its application in achromic and granulating areas. Arch Dermatol 104:592-600, 1971.
58. Falabella R. Surgical therapies for vitiligo. Clin Dermatol 15(5):927-939, 1997.
59. Leiner AB, Halaban R, Klaus SN. Transplantation of human melanocytes. J Invest Dermatol 89:219-224, 1987.
60. Lontz W, Olsson MJ, Moellman G, et al. Pigment cell transplantation for treatment of vitiligo: a progress report. J Am Acad Dermatol 30:591-597, 1994.
61. Olsson MJ, Juhlin L. Transplantation of melanocytes in vitiligo. Br J Dermatol 132:587-591, 1995.
62. Plott RT, Brysk MM, Newton R, et al. A surgical treatment for vitiligo: autologous cultured-epithelial grafts. J Dermatol Surg Oncol 15:1161-1166, 1989.
63. Olsson MJ, Juhlin I. Leucoderm treated by transplantation of basal cell layer enriched suspension. Br J Dermatol 138:644-648, 1998.
64. Na GY, Seo SK, Choi SK. Single hair grafting for the treatment of vitiligo. J Am Acad Dermatol 38:580-584, 1998.
65. Khan AM, Cohen MJ, Kaplan L, et al. Vitiligo: treatment by dermabrasian and epithelial sheet grafting. J Am Acad Dermatol 33:646-648, 1995.
66. Kahn AM, Ostad A, Moy RL. Grafting following short-pulse carbon dioxide laser deepithelialization. Dermatol Surf 22:965-968, 1996.
67. Kaufman R, Greiner D, Kypenberger S, Bernd A. Grafting in vitro cultured melanocytes onto laser-ablated lesions in vitiligo. Octa Derm Venereol 78:136-138, 1998.
68. Yang JS, Kye VC. Treatment of vitiligo with autologous epidermal grafting by means of pulsed erbium: YAG laser. J Am Acad Dermatol 38:280-282, 1998.
69. Halder RM, Pham H, Breadon JY, Johnson BA. Micropigmentation for the treatment of vitiligo. J Dermatol Surg Oncol 15:1092-1098, 1989.